DOCSLIB.ORG

'Fearonomics' and the Role of the Private Sector in the Nigerian Ebola

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
'Fearonomics' and the Role of the Private Sector in the Nigerian Ebola ‘Fearonomics’ and the Role of the Private Sector in the Nigerian Ebola Response by Sulzhan Bali Duke Global Health Institute Duke University Date: Approved: ___________________________ Kearsley Stewart, Co-Supervisor ___________________________ Muhammad Pate, Co-Supervisor ___________________________ Chris Woods Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in the Duke Global Health Institute in the Graduate School of Duke University 2016 ABSTRACT ‘Fearonomics’ and the Role of the Private Sector in the Nigerian Ebola Response by Sulzhan Bali Duke Global Health Institute Duke University Date: Approved: ___________________________ Kearsley Stewart, Co-Supervisor ___________________________ Muhammad Pate, Co-Supervisor ___________________________ Chris Woods An abstract of a thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in the Duke Global Health Institute in the Graduate School of Duke University 2016 Copyright by Sulzhan Bali 2016 Abstract Background: Outbreaks of infectious diseases such as Ebola have dramatic economic impacts on affected nations due to significant direct costs and indirect costs, as well as increased expenditure by the government to meet the health and security crisis. Despite its dense population, Nigeria was able to contain the outbreak swiftly and was declared Ebola free on 13 th October 2014. Although, Nigeria’s Ebola containment success was multifaceted, the private sector played a key role in Nigeria’s fight against Ebola. An epidemic of a disease like Ebola, not only consumes health resources, but also detrimentally disrupts trade and travel to impact both public and private sector resulting in the ‘fearonomic effect ’ of the contagion. In this thesis I have defined ‘ fearonomics ’ or the ‘ fearonomic effects ’ of a disease as the economic effects of both informed and misinformed aversion behavior exhibited by individuals, organizations, or countries during an outbreak. During an infectious disease epidemic, there is a significant potential for public-private sector collaborations that can help offset some of the government’s cost of controlling the epidemic. Objective: The main objective of this study is to understand the ‘ fearonomics’ of Ebola in Nigeria and to evaluate the incentives and the role of the key private sector stakeholders in Nigeria’s Ebola response. Methods: This qualitative retrospective study was conducted in Nigeria and utilizes grounded theory to look across different economic sectors in Nigeria to understand the impact of Ebola on Nigeria’s private sector and how it dealt with the various challenges posed by the disease and its ‘fearonomic effects’. iv Results: Due to swift containment of Ebola in Nigeria, the economic impact of the disease was limited especially in comparison to the other Ebola infected countries such as Liberia, Sierra Leone, and Guinea. However, the 2014 Ebola outbreak had more than just direct impact on the country’s economy and despite the swift containment, no economic sector was immune to the disease’s fearonomic impact. The potential scale of the fearonomic impact of a disease like Ebola on the private sector was one of the key motivators for the private sector engagement in the Ebola response. The private sector in Nigeria played an essential role in facilitating the country’s response to Ebola. The private sector not only provided in-cash donations but significant in-kind support to both the Federal and State governments during the outbreak. Swift establishment of an Ebola Emergency Operation Centre (EEOC) was essential to the country’s response and was greatly facilitated by the private sector, showcasing the crucial role of private sector in the initial phase of an outbreak. The private sector contributed to Nigeria’s fight against Ebola not only by donating material assets but by continuing operations and partaking in knowledge sharing and advocacy. Some sector such as the private health sector, telecom sector, financial sector, oil and gas sector played a unique role in orchestrating the Nigerian Ebola response and were among the first movers during the outbreak. This paper utilizes the lessons from Nigeria’s containment of Ebola to highlight the potential of public-private partnerships in preparedness, response, and recovery during an outbreak. v Dedication I would like to dedicate this thesis to the memory and spirit of my grandmother Late Sharda Dutta. I would also like to dedicate this thesis to the memory of my room-mate in Lagos- Late Doyin Sarah Fagbnero. vi Contents Abstract ........................................................................................................................................... iv List of Tables .................................................................................................................................. xi List of Figures ................................................................................................................................ xii Acknowledgements ....................................................................................................................... xiv CHAPTER 1. Introduction ............................................................................................................... 1 1.1. The 2014 West African Ebola Outbreak ............................................................................ 2 1.2. Ebola in Nigeria .................................................................................................................. 4 1.3.The Cost of Ebola Outbreak ................................................................................................ 6 1.4. Private Sector in Disaster Relief........................................................................................ 9 1.5. Impact and Gaps in the Literature .................................................................................... 10 1.6. Objectives and Aims ........................................................................................................ 13 CHAPTER 2. Methodology ........................................................................................................... 14 2.1. Key Terms ........................................................................................................................ 14 2.2 Setting ................................................................................................................................ 14 2.3 Study Design ..................................................................................................................... 15 2.4. Recruitment and Sampling ............................................................................................... 17 2.4.1. In-depth Interview ....................................................................................................... 17 2.4.2. Surveys ........................................................................................................................ 19 2.5. Data Collection ................................................................................................................. 19 2.5.1 In-depth Interviews ...................................................................................................... 21 2.5.2 Survey........................................................................................................................... 21 vii 2.6. Data Analysis ................................................................................................................... 24 2.7. Ethics ................................................................................................................................ 26 CHAPTER 3. RESULTS- Fearonomics of Ebola ......................................................................... 27 3.1. Timeline of Ebola in Nigeria ............................................................................................ 27 3.2. ‘Will Ebola reach Nigeria?’ - Differences across companies in perceived reach of Ebola ................................................................................................................................................. 32 3.3 Understanding the impact of Ebola in Nigeria and the ‘Fearonomics’ of the disease....... 33 3.3.1 How did the misinformation and rumors drive the fearonomic effect? ....................... 33 3.3.1.a Rumors and misinformation promote high-risk behavior ..................................... 36 3.3.1.b Rumors and misinformation and can result in malicious behavior ....................... 39 3.3.1.c Misinformation regarding the transmission of Ebola ............................................ 40 3.4. What were the social and behavioral effects of Ebola on the private sector? .................. 43 3.4.1 Sales of hygiene products increased abnormally .......................................................... 44 3.4.1a Why did the price of sanitizers increase and why was it not profitable for the private sector? ................................................................................................................... 48 3.4.1b How did the outbreak impact the sales of non-sanitizer hygiene products, diinfectants, and medicines? ............................................................................................. 50 3.4.1.c How did the outbreak impact sale of food?........................................................... 53 3.4.2. How did the fearonomic effect manifest into stigma
Load more

Recommended publications
  • List of Participants As of 30 April 2013
    World Economic Forum on Africa List of Participants As of 30 April 2013 Addis Ababa, Ethiopia, 9-11 May 2012 Messumbe Stanly Paralegal The ABENG Law Firm Cameroon Abane Yilkal Abate Secretary-General ICT Association of Ethiopia Ethiopia Zein Abdalla Chief Executive Officer PepsiCo Europe Switzerland Amin Abdulkader Minister of Culture and Tourism of Ethiopia Rakeb Abebe Chief Executive Officer and Founder GAWT International Business Ethiopia Plc Olufemi Adeyemo Group Chief Financial Officer Oando Plc Nigeria Tedros Adhanom Minister of Health of Ethiopia Ghebreyesus Tedros Adhanom Minister of Health of Ethiopia Ghebreyesus Olusegun Aganga Minister of Industry, Trade and Investment of Nigeria Alfredo Agapiti President Tecnoservice Srl Italy Pranay Agarwal Principal Adviser, Corporate Finance MSP Steel & Power Ltd India and Strategy Vishal Agarwal Head, sub-Saharan Africa Deals and PwC Kenya Project Finance Pascal K. Agboyibor Managing Partner Orrick Herrington & Sutcliffe France Manish Agrawal Director MSP Steel & Power Ltd India Deborah Ahenkorah Co-Founder and Executive Director The Golden Baobab Prize Ghana Halima Ahmed Political Activist and Candidate for The Youth Rehabilitation Somalia Member of Parliament Center Sofian Ahmed Minister of Finance and Economic Development of Ethiopia Dotun Ajayi Special Representative to the United African Business Roundtable Nigeria Nations and Regional Manager, West Africa Abi Ajayi Vice-President, Sub-Saharan Africa Bank of America Merrill Lynch United Kingdom Coverage and Origination Clare Akamanzi Chief Operating Officer Rwanda Development Board Rwanda (RDB) Satohiro Akimoto General Manager, Global Intelligence, Mitsubishi Corporation Japan Global Strategy and Business Development Adetokunbo Ayodele Head, Investor Relations Oando Plc Nigeria Akindele Kemi Lala Akindoju Facilitator Lufodo Academy of Nigeria Performing Arts (LAPA) World Economic Forum on Africa 1/23 Olanrewaju Akinola Editor This is Africa, Financial Times United Kingdom Vikram K.
    [Show full text]
  • Fighting Ebola: a Strategy for Action
    FIGHTING EBOLA: A STRATEGY FOR ACTION Vera Songwe, Nonresident Senior Fellow, Africa Growth Initiative THE PRIORITY Despite these overwhelming numbers, prog- ress is being made in the fight against these African populations continue to suffer under diseases. For example, malaria mortality rates in the heavy burden of disease despite overall sus- children in Africa were reduced by an estimat- tained increases in income levels over the last ed 54 percent between 2002 and 2012. Since decade. Three major diseases are among those 2000, there has been a 49 percent reduction responsible for health crises: malaria, HIV/AIDS in the overall malaria mortality rates in Africa. and tuberculosis, and, in 2014, the Ebola virus For HIV, by the end of 2012, about 68 percent emerged as a fourth virus with pandemic po- of eligible persons were receiving antiretroviral tential. treatment, an increase of more than 90 percent since 2009 (UNAIDS 2013). In 2012, for example, 80 percent of the estimat- ed 207 million malaria cases worldwide were However, 2014 in West Africa will be remem- found in Africa, and 90 percent of the estimat- bered not for progress made in combatting in- ed 627,000 global malaria deaths occurred in fectious diseases but as the year the Ebola virus Africa. On average, malaria kills a child every crippled three countries on the continent and minute, of which 90 percent occur among Afri- inflicted economic damage to many others. can children. Malaria-related anemia is estimat- The 20th Ebola outbreak globally has captured ed to cause thousands of deaths a year—and the attention of the world like none of the oth- for countries with endemic malaria, it is estimat- ers that have preceded it and like no other dis- ed that there is a 1.3 percentage point loss in ease has in recent history.
    [Show full text]
  • Ebola Viral Disease Outbreak-2014: Implications and Pitfalls
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE OPINION ARTICLE published: 01 Decemberprovided by 2014 Frontiers - Publisher Connector PUBLIC HEALTH doi: 10.3389/fpubh.2014.00263 Ebola viral disease outbreak-2014: implications and pitfalls Mahip Acharya* Independent Researcher, Kathmandu, Nepal *Correspondence: acharyamahip@gmail.com Edited by: Philip Arthur Mackowiak, University of Maryland School of Medicine, USA Reviewed by: Mohammad Mohseni Sajadi, Institute of Human Virology at the University of Maryland School of Medicine, USA Keywords: Ebola virus outbreak, zoonosis, pharmaceutical industries, ethics in drug approval, global health West Africa – consisting of countries hemorrhagic fever outbreak in southern numerous strains of a single virus species such as Guinea, Liberia, Sierra Leone, and Sudan and northern Zaire (5). Ebola viral and their continued mutation – as is the Nigeria – is the westernmost region of the disease, a zoonotic disease, has since been case with the current Ebola infection (8)– African continent. Afflicted by widespread observed intermittently in different regions often stymies the research for anti-viral poverty and political instability,WestAfrica of Central Africa (6), but none of those drugs. This is similar to the case with is one of the poorest regions in the world – has wreaked damage as monumental as the antibiotics, where bacterial resistance is a Liberia, Sierra Leone, and Guinea are ongoing outbreak. chief concern (9). Bacterial and viral dis- respectively ranked 174, 177, and178 out The current Ebola viral disease outbreak eases benefit from the ever-evolving genetic of 187 countries on the United Nations is turning out to be an insidious threat makeup of their agents, which are capable Development Program Human Develop- to the public health of West Africa – and of rapidly rendering a treatment ineffec- ment Index (1).
    [Show full text]
  • Management, Supervision, and Health Care: a Field Experiment
    NBER WORKING PAPER SERIES MANAGEMENT, SUPERVISION, AND HEALTH CARE: A FIELD EXPERIMENT Felipe A. Dunsch David K. Evans Ezinne Eze-Ajoku Mario Macis Working Paper 23749 http://www.nber.org/papers/w23749 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 August 2017, Revised April 2021 The intervention evaluated in this study is the result of a collaboration between the Nigerian Federal Ministry of Health, Nigerian National Primary Healthcare Development Agency (formerly known as the Saving One Million Lives initiative), and the World Bank. We gratefully acknowledge the invaluable support of Marcus Holmlund, Arianna Legovini, Marie Francoise Marie-Nelly, Kelechi Ohiri, Ado J.G Muhammad, Muhammad Ali Pate, and Hong Wang. We are also grateful to Oyebanji Filani, Giacomo de Giorgi, Benjamin Loevinsohn, Oluwole Odutolu, Chinny Ogunro, and participants in various conferences and seminars for helpful comments. We thank Md. Abul Kalam Azad and Ayodele Fashogbon for field coordination and Qiao Wang, Victoria Sung, and Amina Mendez Acosta for research assistance. The research protocol was reviewed and approved by Nigeria’s National Health Research Ethics Committee and the Homewood Institutional Review Board of Johns Hopkins University. This study was made possible through generous funding from the Bill and Melinda Gates Foundation. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications. © 2017 by Felipe A.
    [Show full text]
  • Tech at the Service of the Fight Against Epidemics in West Africa
    Study report for the Pierre Fabre Foundation’s Global South eHealth Observatory Tech at the service of the fight against epidemics in West Africa Born experimentally with Ebola, the use of technology to fight epidemics for a faster, more efficient and social management of the crisis in West Africa, has now reached its full potential with Covid-19, benefitting the health of African populations. Julie LANCKRIET Under the Direction of Samir ABDELKRIM StartupBRICS 1 CONTENTS I. DATAS AGAINST Ebola, OR TECH TO SERVE CRISIS MANAGEMENT ..................................................... 4 A. In an organic and incremental way, the Tech supports the fight against the virus. ......................... 4 1) INFORM AND RAISE AWARENESS ................................................................................................. 5 2) TRACE AND LOCATE ...................................................................................................................... 6 3) DIAGNOSE, COLLECT AND REPORT DATA ..................................................................................... 7 4) TO SUPPORT PEOPLE ECONOMICALLY THROUGH ELECTRONIC TRANSFERS, A PROMISING BUT STILL PREMATURE EXPERIMENT ......................................................................................................... 10 B. Case study: Ebola management in Nigeria, an example of an immediate and controlled response by the Tech. ............................................................................................................................................
    [Show full text]
  • Hand Hygiene Practices During and After Ebola Virus Disease Outbreak Pepple N* and Akpan E Salem University, Lokoja, Nigeria
    ty & Gl afe ob S a l l a H e Pepple and Akpan, Med Saf Glob Health 2017, 6:2 c i a d l t e h M Medical Safety & Global Health DOI: 10.4172/2574-0407/1000137 ISSN: 2574-0407 Research Article Open Access Responses to Epidemic Prevention in Nigeria; Hand Hygiene Practices During and After Ebola Virus Disease Outbreak Pepple N* and Akpan E Salem University, Lokoja, Nigeria Abstract Most infections are thought to be transmitted by contact with an infected person’s body fluid, e.g., Ebola virus disease (EVD). Following the recent EVD outbreak in Nigeria, the essence of this study was to assess the responses to epidemic prevention in Nigeria by individuals and institutions; a comparative study of hand hygiene practices during and after EVD outbreak was carried out. The aim of this study was to indirectly assess the level of the nation’s preparedness to combating disease outbreak by assessing the attitude and practice of hand hygiene among the general population and institutions in Abuja – FCT, Nigeria, after the EVD outbreak and to investigate the presence of the necessary facilities and supplies required for hand hygiene in institutions (schools, banks, hospitals, hotels and NGOs working on healthcare). These institutions were observed to be complying with high hygiene and safety practices and had adequate prevention facilities during the EVD outbreak in Nigeria. A cross-sectional descriptive and observational study was conducted. Observation of the presence of safety facilities and utilization/compliance was conducted at the selected institutions. Staff attitudes and perceptions towards hand hygiene were assessed through self-administered questionnaire to management staff in 10 different institutions: 2 each of schools, hospitals, banks, hotels and health NGOs.
    [Show full text]
  • The Campaign to Kick Polio out of Nigeria
    THE CAMPAIGN TO KICK POLIO OUT OF NIGERIA Adapted from the broadcast audio segment; use the audio player to listen to the story in its entirety. Religion in sub-Saharan Africa is often about saving patients as much as it is about saying prayers. That blend of holy and healthy is on display in Northern Nigeria where the country's religious leadership played a critical role in first preventing and then promoting the campaign to eliminate polio from Africa’s largest population. Dr. Bruce Aylward is the Director of The Global Polio Eradication Initiative. He says people don’t realize just how devastating polio can be – it leaves its victims paralyzed for life. “The acute illness is a very painful disease. The thing that goes unrecognized by many people is that a large proportion of children can actually die of the disease.” Despite decades of vaccination campaigns children are still dying from the disease, particularly in Northern Nigeria. “If you are a polio virus and there is a global war being waged against you, you are going to look for a large, dense population with low immunization coverage, sub-optimal sanitation, and a tropical climate to survive,” says Dr. Aylward. “Those are going to be the keys to your survival and Nigeria had all of those in spades.” The task of defeating the virus got even tougher in 2003 when rumors that the polio vaccine was tainted with sterility drugs and HIV swirled through Northern Nigeria. As concern mounted, Northern Nigeria’s traditional and religious leadership was consulted. Anand Balachandran is the Political Advocacy Officer of the Global Polio Eradication Initiative.
    [Show full text]
  • FAITH and DEVELOPMENT in FOCUS NIGERIA Supported by the International Partnership on Religion and Sustainable Development May 2018
    FAITH AND DEVELOPMENT IN FOCUS NIGERIA Supported by the International Partnership on Religion and Sustainable Development May 2018 WORLD FAITHS DEVELOPMENT DIALOGUE BERKLEY CENTER FOR RELIGION, PEACE & WORLD AFFAIRS FOREWORD ABOUT THE WORLD FAITHS DEVELOPMENT DIALOGUE “Faith and Development in Focus: Nigeria” was positive and informed engagement has the potential commissioned by GIZ to explore how Nigeria’s to contribute to virtually any development endeavor. The World Faiths Development Dialogue (WFDD) is a not-for-profit organization working at the intersection of religion and complex and dynamic religious institutions perceive The fragmented nature of engagement, both among global development. Housed within the Berkley Center in Washington, D.C., WFDD documents the work of faith-inspired the country’s development challenges and are involved religious actors and with the Nigerian government organizations and explores the importance of religious ideas and actors in development contexts. WFDD supports dialogue among across the spectrum of development strategies and its international partners, can undermine their religious and development communities and promotes innovative partnerships, at national and international levels, with the goal of and programs, and vice versa for non-religious potentially positive contributions. Examples of the contributing to positive and inclusive development outcomes. development actors. The report builds on the work of possible consequences of gaps in understanding WFDD and Georgetown University’s Berkley Center include failures to learn from experience, often for Religion, Peace, and World Affairs to analyze through lack of knowledge about what others ABOUT THE INTERNATIONAL PARTNERSHIP ON RELIGION AND SUSTAINABLE and document religious engagement in development are doing; missed opportunities due to limited DEVELOPMENT (PARD) in specific countries.
    [Show full text]
  • Ebola Hemorrhagic Fever Ebola Virus Disease (EVD)
    Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept. of Health & Hospitals 800-256-2748 (24 hr. number) www.infectiousdisease.dhh.louisiana.gov Ebola Hemorrhagic Fever Ebola Virus Disease (EVD) 12/01/2014 “The bottom line with Ebola is we know how to stop it: traditional public health. Find patients, isolate and care for them; find their contacts; educate people; and strictly follow infection control in hospitals. Do those things with meticulous care and Ebola goes away.” Tom Frieden, MD, MPH - Director of the Centers for Disease Control and Prevention This manual is based on the CDC recommendations. It is presented in a very concise format to provide infection preventionists and epidemiologists a single document grouping all information necessary to understand Ebola transmission, patient management and epidemic prevention. This manual is updated weekly. For the most recent information access the CDC website. The word Ebola is sometimes used as a synonym for Ebola Virus Disease. Table of Contents Ebola Hemorrhagic Fever....................................................................................................................... 1 1-Epidemiology ...................................................................................................................................... 6 1.1-The virus ...................................................................................................................................... 6 1.2-Incubation period is important ....................................................................................................
    [Show full text]
  • Vaccines and Other Biologicals
    INDEPENDENT MONITORING BOARD GLOBAL POLIO ERADICATION INITIATIVE (GPEI) SEVENTH MEETING 29 to 31 October 2012 Venue: Royal College of Physicians, Regents Park, London LIST OF PARTICIPANTS IMB MEMBERS Sir Liam Donaldson, Professor of Health Policy, Imperial College, London, UK Dr Nasr El Sayed, Assistant Minister of Health, Egypt Dr Jeffrey Koplan, Vice President for Global Health, Emory Global Health Institute, USA Dr Sigrun Møgedal, Special Advisor, Norwegian Knowledge Center for Health Services Professor Ruth Nduati, Associate Professor of Paediatrics, University of Nairobi, Kenya Dr Ciro de Quadros, Executive Vice President, Sabin Vaccine Institute, USA Dr Arvind Singhal, Professor of Communication, University of Texas at El Paso, USA Professor Michael Toole, Head, Centre for International Health, Burnet Institute, Australia IMB Secretariat Dr Paul Rutter Mr Niall Fry MINISTRY OF HEALTH - AFGHANISTAN Dr Mohammad Taufiq Mashal, Director-General Preventive Medicine, Ministry of Public Health MINISTRY OF HEALTH - ANGOLA Dr. Jose Vieira Dias Van-Dunem, Minister of Health Dr Fátima Valente, Head of Department of Hygiene and Epidemiology MINISTRY OF HEALTH - CHAD Mr Youssouf Hamat Moussa, State Secretary of Health Dr Hamid Djabar, Director of Reproduction Health & Vaccinations MINISTRY OF HEALTH - DR CONGO Dr Kabange numbi Mukwampa Felix, Minister of Health Dr Mulumba wa Kamba Audry, EPI Manager Mr Banze wan Gala Alquin, Ministry of Health MINISTRY OF HEALTH - INDIA Awaiting........ NIGERIA Dr Muhammad Ali Pate, Honorable Minister of State for Health Dr Ado J.G. Muhammad, CEO, National Primary Care Development Agency (NPHCDA) Dr Emmanuel Abanida, Director, NPHCDA Dr M Z Mahmud, CMO, NPHCDA HRH Alh Sa'amaila M Mera, Emir of Argungu & Vice Chair NTLC Ambassdor U.
    [Show full text]
  • UHC2030 Core Team Report
    2030 International Health Partnership International Health Partnership for UHC 2030 Core Team Report 2019 1 2030 International Health Partnership International Health Partnership for UHC 2030 Core Team Report 2019 Copyright UHC2030 2020 2 3 CONTENTS Introduction .......................................................................................................................................................................................6 Box 1 UHC2030: what it is, what it does and how it works ................................................................................... 6 Snapshot of UHC2030 in 2019 ........................................................................................................................................8 Box 2 UHC2030 areas of work .......................................................................................................................................... 7 Box 3 Key commitments, targets and actions in the UN HLM Political Declaration on UHC ................... 11 1. Voice Box 4 UHC Day advocacy activities .............................................................................................................................. 13 1.1 Strategic global advocacy ...............................................................................................................................................10 Box 5 CSEM commentary on the 2019 Global Monitoring Report on UHC ................................................... 13 1.2 Country UHC campaigns ................................................................................................................................................12
    [Show full text]
  • The World Bank
    The World Bank FOR OFFICIAL USE ONLY Report No: PAD4185 Public Disclosure Authorized INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT AND INTERNATIONAL DEVELOPMENT ASSOCIATION PROJECT PAPER ON A PROPOSED ADDITIONAL FINANCING TO THE Public Disclosure Authorized COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PROGRAM USING THE MULTIPHASE PROGRAMMATIC APPROACH (GLOBAL COVID-19 MPA) WITH AN ADDITIONAL IBRD AND IDA FINANCING OF UP TO US$12 BILLION (OF WHICH UP TO US$6 BILLION FROM IDA AND UP TO US$6 BILLION FROM IBRD) Public Disclosure Authorized October 13, 2020 Human Development Practice Group This document has a restricted distribution and may be used by recipients only in the performance of their official duties. Its contents may not otherwise be disclosed without World Bank authorization. Public Disclosure Authorized Vice President: Mamta Murthi Global Director: Muhammad Ali Pate Practice Manager: Feng Zhao Task Team Leader(s): David Wilson, Jumana Qamruddin, Mary T. Mulusa Nadeem Mohammad, John Anderson, Lucy Kang’arua, Louise Task Team Members: Ashton, Luis Osorio Florez, Howard Bariira Centenary, Rajeev K. Swami, Shirmila T. S. Ramasamy, Christopher Finch ABBREVIATIONS AND ACRONYMS AF Additional Financing AIIB Asian Infrastructure Investment Bank BFP Bank Facilitated Procurement CDC Center for Disease Control and Prevention CEPI Coalition for Epidemic Preparedness Innovations COVAX AMC COVID-19 Vaccines Global Access Advance Market Commitment COVAX Facility COVID-19 Vaccines Global Access Facility COVID-19 Coronavirus Disease 2019
    [Show full text]